Later this year, Merck expects to refile Arcoxia in the U.S. and either spin off or do an initial public offering for its pharmacy-benefits manager unit, Medco.
The biggest newcomers immediately land on the list by way of initial public offerings or spin-offs of major subsidiaries of their former parent companies, who are also on our list.